Immunotherapy combo may boost liver cancer ablation success
NCT ID NCT06045975
First seen Apr 26, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This study tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard liver cancer ablation procedure can help keep the cancer from coming back. About 30 adults with early-stage liver cancer will receive one infusion of the drug combination, then undergo ablation, followed by 11 monthly infusions of durvalumab alone. The main goal is to see how long patients stay free of local recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospitl Avicenne
Bobigny, 93000, France
Conditions
Explore the condition pages connected to this study.